A Phase I Study of Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer.

Trial Profile

A Phase I Study of Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Dovitinib (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Apr 2016 Status changed from suspended to discontinued.
    • 04 Feb 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 27 Jul 2012 Actual initiation date (Jul 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top